New
Associate Director, Stability
Ardelyx | |
United States, Massachusetts, Waltham | |
Feb 12, 2026 | |
|
Description
Ardelyx is a publicly traded commercial biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA (tenapanor) and XPHOZAH (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada.
Position Summary:The Associate Director, Stability is a self-motivated individual who works as a member of an integrated team at Ardelyx contracting, designing, managing, and evaluating stability studies at contractors for both drug substance and drug product. This individual should have the breadth of experience required to manage stability studies in early stage as well as in commercial stage. This individual should have a good knowledge of ICH and cGMP guidelines and the ability to contribute to regulatory filings as needed for stability.
Please note: this position is a hybrid-based out of our Waltham, MA or Newark, CA office and requires a presence on-site 2-3 days per week.
Responsibilities:
Qualifications:
| |
Feb 12, 2026